Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group.
Waters L, et al. Among authors: stellbrink hj.
Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827.
Clin Infect Dis. 2023.
PMID: 36259527
Clinical Trial.